Journal of Cardiovascular Pharmacology最新文献_第3页

The Effects of Anakinra on Cardiorespiratory Fitness in Heart Failure Stratified by Age in Phase II Clinical Trials. 在II期临床试验中，阿那白对按年龄分层的心力衰竭患者心肺健康的影响。

IF 2.2 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-09-09 DOI: 10.1097/FJC.0000000000001756

Austin C Hogwood, Michele Golino, Francesco Moroni, Justin M Canada, Marco G Del Buono, Ross Arena, Benjamin Van Tassell, Antonio Abbate

{"title":"The Effects of Anakinra on Cardiorespiratory Fitness in Heart Failure Stratified by Age in Phase II Clinical Trials.","authors":"Austin C Hogwood, Michele Golino, Francesco Moroni, Justin M Canada, Marco G Del Buono, Ross Arena, Benjamin Van Tassell, Antonio Abbate","doi":"10.1097/FJC.0000000000001756","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001756","url":null,"abstract":"Cardiorespiratory fitness (CRF) in heart failure (HF) declines with age. Interleukin-1 (IL-1) is a pro-inflammatory cytokine involved in aging and HF. We aimed to determine the changes in CRF before and after treatment with anakinra, recombinant IL-1 receptor antagonist, in patients with HF stratified according to age below and above 60 years in phase II clinical trials. We analyzed data from 73 patients (37 [51%] female), 49 (67%) patients ˂60 years and 24 (33%) ≥60 years. All patients received anakinra 100 mg subcutaneously daily for a median of 4 (interquartile range from 2 to 12) weeks. We measured peak oxygen consumption (VO2peak) and high-sensitivity C-reactive protein (hsCRP). When compared with older patients, younger patients had higher baseline peak VO2 (15.2 [12.4-17.7] vs. 12.4 [10.3-14.3] mL·kg-1·min-1, p=0.001), yet no significant differences in hsCRP (6.6 [3.6-16.6] vs. 5.2 [2.7-11.2] mg/L, p=0.18). In both groups, anakinra decreased hsCRP (<60 years: -3.6 [-8.1 to -1.9] mg/L; p<0.001; ≥60 years: -2.7 [-9.0 to -1.4] mg/L; p<0.001) and increased peak VO2peak (<60 years: +0.5 [-0.9 - 2.5] mL·kg-1·min-1; p=0.036; ≥60 years: +1.1 [0.2 - 2.3] mL·kg-1·min-1; p<0.001). No significant differences in changes across time were observed between the age groups. Older patients with HF have a greater baseline impairment in CRF compared to younger patients despite similar levels of systemic inflammation, and they appear to have a similar improvement in CRF following treatment with anakinra. The lack of an active control group (placebo) is a significant limitation and additional studies are needed to validate and expand these findings assessing clinical outcomes.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heart Rate Lowering With Ivabradine and Burden of Symptoms in Patients With Postural Orthostatic Tachycardia Syndrome. 伊伐布雷定降低心率与体位性心动过速综合征患者的症状负担。

IF 2.2 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-08-26 eCollection Date: 2025-09-01 DOI: 10.1097/FJC.0000000000001754

Michele Marchetta, Rocio I Lopez, Austin C Hogwood, Georgia Thomas, Gerardina Abbate, Roshanak Markley, Justin M Canada, Antonio Abbate

引用次数: 0

Current Practices and Perspectives on the Use of Intravenous Vasodilators in Acute Heart Failure: An International Survey. 静脉血管扩张剂在急性心力衰竭治疗中的应用现状与展望：一项国际调查。

IF 2.2 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-08-20 DOI: 10.1097/FJC.0000000000001753

Alessandro Galluzzo, Maurizio Bertaina, Julie K K Vishram-Nielsen, Massimiliano Camilli, Hannah Schaubroeck, Marco Marini, Ferdinando Varbella, Luca Monzo, Finn Gustafsson, Frank Ruschitzka, Wilfried Mullens

{"title":"Current Practices and Perspectives on the Use of Intravenous Vasodilators in Acute Heart Failure: An International Survey.","authors":"Alessandro Galluzzo, Maurizio Bertaina, Julie K K Vishram-Nielsen, Massimiliano Camilli, Hannah Schaubroeck, Marco Marini, Ferdinando Varbella, Luca Monzo, Finn Gustafsson, Frank Ruschitzka, Wilfried Mullens","doi":"10.1097/FJC.0000000000001753","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001753","url":null,"abstract":"Although a solid pathophysiological rationale supports intravenous vasodilators (IVV) for acute heart failure (AHF), trial evidence is conflicting and international guidelines offer only weak recommendations. We conducted an international survey to capture contemporary, real-world practice and clinician opinion regarding IVV use in AHF. A 29-item, web-based questionnaire was distributed to cardiologists involved in AHF management. Items explored indications, contraindications, preferred agents, monitoring strategies, and interaction with guideline-directed medical therapy. We analysed responses from 170 physicians in 32 countries (67 % male; mostly aged 30-50 years). Sixty-two percent treat fewer than ten patients per month with IVV; nitroglycerin is the drug of choice for 48%, followed by sodium nitroprusside in 29%. Nearly half (48%) would start IVV also out of the intensive-care setting and 58% consider repeated non-invasive blood-pressure monitoring sufficient. Key indications are acute decompensated HF (88%) and pulmonary oedema (87%), yet 42 % would also use IVV for advanced low-output HF, 25% for cardiogenic shock, and 24% for isolated right ventricular failure. Hypotension is cited as the principal contraindication (51%), although the reported thresholds for blood pressure vary widely. Respondents favour IVV in reduced or mildly reduced ejection fraction (55%) more often than in preserved EF (17%). Opinions diverge sharply on whether to pause or continue oral neuro-hormonal therapies during infusion. This survey shows that IVV are used in a limited number of AHF patients and practice is highly heterogeneous across centres. These findings underscore the need for prospective trials to clarify which subsets derive haemodynamic or prognostic benefit.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Landscape of Berberine Targets: A Potential Pharmacological Insight for Heart failure Treatment. 小檗碱靶点景观：心力衰竭治疗的潜在药理学见解。

IF 2.2 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-08-20 DOI: 10.1097/FJC.0000000000001750

Siao Wen, Xiehong Liu, Liping Liu, Yongjun Hu, Qinghai Zhang

{"title":"Landscape of Berberine Targets: A Potential Pharmacological Insight for Heart failure Treatment.","authors":"Siao Wen, Xiehong Liu, Liping Liu, Yongjun Hu, Qinghai Zhang","doi":"10.1097/FJC.0000000000001750","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001750","url":null,"abstract":"Berberine, the primary active compound in Coptis chinensis Franch., is well-known for its anti-infective, hypoglycemic, lipid-lowering, anti-tumor, and anti-inflammatory effects. This review summarizes the physicochemical and pharmacokinetic characteristics of berberine, its intra-intestinal pharmacology involving gut microbiota cross-talk to heart failure (gut-cardiac axis), extraintestinal pharmacology in heart failure, and network pharmacology. Berberine enhances the intestinal barrier, reducing endotoxin entry into the bloodstream. It also regulates the intestinal flora composition, notably altering the Bacillota/Bacteroidota ratio. Importantly, berberine promotes beneficial bacteria while inhibiting pathogenic bacteria. Additionally, it influences gut microbiota metabolites, decreasing trimethylamine (TMA) and trimethylamine N-oxide (TMAO) while increasing short-chain fatty acids (SCFAs). Berberine addresses extraintestinal direct mechanisms by mitigating heart failure risk factors such as atherosclerosis, hyperglycemia, and hyperlipidemia. It also decreases cardiac oxygen consumption, oxidative stress, and ER stress, thereby reducing chronic cardiac inflammation, apoptosis, and remodeling, while enhancing myocardial energy to improve cardiac function. Network pharmacology analysis has identified the top 10 hub genes for berberine in heart failure therapy: STAT3, TNF, MTOR, NFKB1, HIF1A, ESR1, BCL2, PTGS2, PPARG, and MMP9. Notably, TNF, HIF1A, and PPARG are key targets for berberine in heart failure with preserved ejection fraction (HFpEF) treatment. Berberine shows promise for heart failure treatment, but its bioavailability needs improvement. Additionally, the efficacy and safety of berberine in clinical heart failure management, especially in HFpEF, require further evaluation through large-scale, multicenter clinical trials.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lactylation in Cardiovascular Diseases: Epigenetic Mechanisms and Therapeutic Potential. 心血管疾病中的乳酸酰化：表观遗传机制和治疗潜力。

IF 2.2 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-08-15 DOI: 10.1097/FJC.0000000000001751

Meican Ma, Chong Xu, Hong Zhou, Yu Zhou

引用次数: 0

Integration of vascular smooth muscle cell phenotypic switching and senescence. 血管平滑肌细胞表型转换与衰老的整合。

IF 2.2 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-08-15 DOI: 10.1097/FJC.0000000000001752

Shiqi Deng, Xinglei Yin, Ruigong Zhu

{"title":"Integration of vascular smooth muscle cell phenotypic switching and senescence.","authors":"Shiqi Deng, Xinglei Yin, Ruigong Zhu","doi":"10.1097/FJC.0000000000001752","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001752","url":null,"abstract":"Cardiovascular diseases (CVDs) are life-threatening conditions with multifactorial causes. As the most abundant cells in the vascular wall, vascular smooth muscle cells (VSMCs) play a crucial role in regulating vascular tone. Under physiological conditions, VSMCs predominantly demonstrate a contractile phenotype. However, this phenotype can be altered in response to microenvironmental stimuli, particularly during injury or pathological conditions. We performed a systematic literature review to examine the phenotypic switching of VSMCs from a contractile state to a dedifferentiated state, as well as the role of senescence in VSMC dysfunction. Special attention was given to the impact of microenvironmental stress on VSMCs transdifferentiation into multiple phenotypes, including macrophage-like cells, foam cells, and mesenchymal stem cells. Prolonged or excessive phenotypic switching of VSMCs leads to cellular senescence, characterized by decreased proliferative capacity, increased secretion of inflammatory factors (SASP), and a tendency toward calcification. Senescent VSMCs undergo transdifferentiation into multiple phenotypes, which promote arterial calcification and fibrosis, thereby exacerbating cardiovascular disease progression. Emerging evidence reveals that VSMC phenotypic switching and senescence share common molecular pathways, offering new opportunities for developing dual-target therapies against age-related cardiovascular diseases by simultaneously modulating cellular plasticity and aging processes.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144855298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Human-Based Technologies in Cardiovascular Pharmacology Research. 心血管药理学研究中的人本技术。

IF 2.2 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-08-05 DOI: 10.1097/FJC.0000000000001745

Giuseppe Biondi-Zoccai, Giacomo Frati, Roberto Carnevale, George W Booz

{"title":"Human-Based Technologies in Cardiovascular Pharmacology Research.","authors":"Giuseppe Biondi-Zoccai, Giacomo Frati, Roberto Carnevale, George W Booz","doi":"10.1097/FJC.0000000000001745","DOIUrl":"10.1097/FJC.0000000000001745","url":null,"abstract":"Human-based technologies are revolutionizing cardiovascular pharmacology by offering innovative platforms that more accurately reflect human biology and disease mechanisms than traditional animal models. These approaches include tissue chips, microphysiological systems, engineered heart tissues, cardiac organoids, and human cardiac slices-each contributing to substantial improvements in drug testing, mechanistic understanding, and translational relevance. Complementary advances in biobanking, omics technologies, and advanced imaging offer the opportunity for multidimensional characterization of cardiovascular phenotypes, while digital health tools and wearables expand our translational armamentarium with real-time physiological monitoring and decentralized clinical trials. Artificial intelligence and machine learning further contribute discovery pipelines by facilitating data integration and predictive modeling. The application of CRISPR/Cas9 genome editing and in vitro to in vivo extrapolation frameworks underscores the growing precision and clinical orientation of these methodologies. Together, these innovations are reshaping basic research, drug development, regulatory science, and personalized medicine in cardiology. However, to fully realize their promise, challenges related to standardization, scalability, and ethical governance must be addressed. With strategic investment and cross-sector collaboration, human-based approaches are poised to lead the next generation of cardiovascular research-delivering safer, more effective therapies tailored to human-specific biology.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12462779/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144789259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of rosuvastatin and vitamin K on vascular calcification in a rat model of adenine induced chronic kidney disease. 瑞舒伐他汀和维生素K对腺嘌呤诱导的慢性肾病大鼠模型血管钙化的影响。

IF 2.2 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-08-04 DOI: 10.1097/FJC.0000000000001748

Sherouk S Shams, Mohamed T Ghoneim, Doaa A Ghareeb, Aliaa A Masoud, Hend S Zakaria

{"title":"Effect of rosuvastatin and vitamin K on vascular calcification in a rat model of adenine induced chronic kidney disease.","authors":"Sherouk S Shams, Mohamed T Ghoneim, Doaa A Ghareeb, Aliaa A Masoud, Hend S Zakaria","doi":"10.1097/FJC.0000000000001748","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001748","url":null,"abstract":"Vascular calcification (VC) is prevalent in patients with chronic kidney disease and raises the risk of cardiovascular death. The study aimed to evaluate the protective effects of rosuvastatin and/or vitamin K on VC in a rat model of adenine-induced CKD and to explore the potential underlying mechanisms. Forty Wistar albino rats were divided equally into five groups: rats of group I (control group) received drug vehicle, rats of group ΙΙ received an adenine containing diet, rats of group IIİ received an adenine-containing diet + oral rosuvastatin (5 mg/kg/day), rats of group ΙV received an adenine-containing diet + oral vitamin K (40 mg/kg/day) and rats of group V received adenine containing diet and combined treatment of rousvastatin and vitamin K. The entire experiment last for five weeks. Then, aortas and kidneys were collected for biochemical and histopathological analysis. Oxidative stress and inflammation markers were measured in kidney and aortic homogenates, whereas alkaline phosphatase (ALP) activity, osteocalcin and bone morphogenic protein-2 levels and autophagic markers were measured in aortic hemogenates. Treatment with rosuvastatin and/ or vitamin K improved renal function and decreased aortic calcium accumulation. Additionally, they decreased ALP activity and osteogenic markers level while increasing the expression of autophagic markers. The beneficial effects of rosuvastatin and/ or vitamin K are further supported by histopathological examination of aortas and kidneys. The combined treatment produced the best outcomes in all studied parameters. The study concluded that rosuvastatin and/ or vitamin K could improve VC by combating oxidative stress, decreasing inflammation and autophagy upregulation.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rationale and Design of the SOTA-THROMBOSIS Trial (ATRU-VI): Antithrombotic Activities of Sotagliflozin compared to Empagliflozin. SOTA-THROMBOSIS试验的基本原理和设计（ATRU-VI）：与恩帕列净相比，索他列净的抗血栓活性。

IF 2.2 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-08-01 DOI: 10.1097/FJC.0000000000001747

Juan Antonio Requena-Ibáñez, Mohammad Urooj Zafar, Marcos Ferrandez-Escarabajal, Gines Escolar, Carlos Santos-Gallego, David Lam, Juan José Badimon

{"title":"Rationale and Design of the SOTA-THROMBOSIS Trial (ATRU-VI): Antithrombotic Activities of Sotagliflozin compared to Empagliflozin.","authors":"Juan Antonio Requena-Ibáñez, Mohammad Urooj Zafar, Marcos Ferrandez-Escarabajal, Gines Escolar, Carlos Santos-Gallego, David Lam, Juan José Badimon","doi":"10.1097/FJC.0000000000001747","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001747","url":null,"abstract":"While selective SGLT2 inhibitors improve heart failure (HF) outcomes, they do not consistently reduce atherothrombotic events (myocardial infarctions and strokes). Clinical trials with sotagliflozin, the first dual SGLT1/2 inhibitor, have shown significant reductions in both HF outcomes and atherothrombotic events; an effect not seen with highly-selective SGLT2 inhibitors like empagliflozin. This effect may be related to SGLT1 inhibition, as SGLT1 is widely expressed in the myocardium, platelets, and endothelial cells, suggesting a potential antithrombotic mechanism. The SOTA-THROMBOSIS trial is a randomized, cross-over study in healthy volunteers (n=16) comparing the antithrombotic effects of dual SGLT1/2 inhibition with sotagliflozin and selective SGLT2 inhibition with empagliflozin. All participants will receive each treatment for 4-weeks, separated by a one-month washout. Blood thrombogenicity under high and low shear rate conditions will be assessed using the Badimon perfusion chamber. Additional assessments include platelet aggregation (Multiplate Analyzer) and clot formation kinetics using thromboelastometry (RoTEM). Measurements will be performed at baseline (pre-treatment) and at the end of each treatment period. The cross-over design - where each participant receives both study treatments and serves as his/her own control - significantly reduces both, intra-subject and intra-group variability. We hypothesize that both treatments will reduce blood thrombogenicity compared to baseline, with sotagliflozin offering a more marked antithrombotic effect than empagliflozin. This trial will provide novel mechanistic insights into the antithrombotic activity of SGLT1/2 inhibition. If confirmed, these findings may explain the additional cardiovascular protection observed with sotagliflozin and support its use in HF patients at high thrombotic risk.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144760201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of regular exercise and resveratrol on hypertension-induced cellular stress response and senescence in renal and vascular tissues of rats. 规律运动和白藜芦醇对高血压大鼠肾和血管组织细胞应激反应及衰老的影响。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-07-24 DOI: 10.1097/FJC.0000000000001744

Nur Banu Bal, Gökhan Sadi, Aykut Bostanci, Saba Kiremitci, Inga Adanir, Mecit Orhan Uludag, Emine Demirel-Yilmaz

{"title":"Effect of regular exercise and resveratrol on hypertension-induced cellular stress response and senescence in renal and vascular tissues of rats.","authors":"Nur Banu Bal, Gökhan Sadi, Aykut Bostanci, Saba Kiremitci, Inga Adanir, Mecit Orhan Uludag, Emine Demirel-Yilmaz","doi":"10.1097/FJC.0000000000001744","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001744","url":null,"abstract":"Hypertension remains the leading cause of morbidity and mortality worldwide and requires more understanding of its molecular basis. This study investigated cellular stress responses and senescence signaling in vascular and renal tissues of DOCA-salt hypertensive rats and the effect of resveratrol and exercise on these processes. Biochemical measurements in plasma and molecular (using Western Blot and qRT-PCR methods) and histopathologic (Hematoxylin-Eosin and Masson's Trichrome staining) examinations in the kidney and aorta were performed. The increase in kidney weight, kidney/body weight ratio, plasma BUN and creatinine levels of hypertensive animals was improved by exercise and resveratrol. Both interventions reduced GRP78/p-PERK-mediated ER stress and restored mitophagy via PINK1-SIRT3 in hypertensive renal and vascular tissues. Decreased vascular enos mRNA expression in hypertensive rats was enhanced by resveratrol treatment. The expression of NLRP3 inflammasome-related molecules and nf-ĸb in both tissues was increased in hypertensive animals. The positive effect of both treatments on inflammatory parameters was more pronounced in the kidney than in the aorta. The increased cellular senescence-related molecules p53 and il-6 were reversed by exercise and resveratrol in both tissues of hypertensive rats. Hypertension caused more obvious structural and inflammatory histopathologic changes in renal tissue than in vascular tissue. Regular exercise ameliorated these hypertension-induced renal alterations more than resveratrol. This study revealed that hypertension induces cellular stress responses including ER stress, impaired mitophagy, inflammation and consequently senescence, leading to structural alterations in a tissue-dependent manner. Regular exercise and resveratrol have different positive regulatory effects on these renal and vascular impairments caused by hypertension.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0